Delivery Order SPE2DB20D2104-SPE2DB25FMZTM
- Not listed
- The Defense Logistics Agency awarded a $17,556.44 firm fixed price delivery order to AmerisourceBergen Drug Corp for 60-tablet bottles of Xifaxan 550 mg on September 12, 2025, with a completion date of September 15, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a competitive delivery order valued at $4,651.90 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on September 12, 2025, with an ultimate completion date of September 15, 2025. This order will be fulfilled from the contractor's corporate office location in Conshohocken, Pennsylvania, using firm fixed pricing with no set-aside designation. The award represents a child delivery order under AmerisourceBergen's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed-price contract with a ceiling value of $13,089.77 and an ultimate completion date of September 15, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed price contract valued at $12,267.73. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The ultimate completion date...
- The Defense Logistics Agency awarded a delivery order valued at $12,991.41 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count) with a ceiling value of $3,532.41. This competitive award, utilizing firm fixed-price terms, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $3,332.48 to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on September 11, 2025, with completion scheduled for September 12, 2025. This non-competitive, firm fixed-price delivery order represents a small-value transaction under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The work will be performed at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed price contract valued at $4,888.67. This competitively awarded delivery order, with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $6,885.33 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitive award, which utilized firm fixed pricing with no set-aside designation, represents a pharmaceutical delivery under the company's existing contract vehicle with DLA. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $5,583.40 to AmerisourceBergen Drug Corp for 60 tablets of Xifaxan 550 mg on April 21, 2025, with an ultimate completion date of April 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMZTMDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,683.99 for 60 tablets of Xifaxan 550 mg on September 8, 2025, with completion scheduled for September 9, 2025. This competitive award utilizes a firm fixed-price contract type with no set-aside designation. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) designated SPE2DX with the DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a prime pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. The company's comprehensive IDC vehicle enables the supply of a broad range of pharmaceutical products, including brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support Defense Health Agency and other federal healthcare customers globally. The Xifaxan delivery order exemplifies the company's capability to fulfill federal medical supply requirements through competitive procurement processes with pricing that demonstrates versatility across transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 9/8/25 |